Table 3.
Change in MADRS score at 25th-28th day of esketamine treatment.
| Author, Year | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Canuso, C.M. 2018 [33] [a] | Fedgchin, M. 2019 [34] [b] | Popova, V. 2019 [35] [c] | Ochs-Ross, R. 2020 [38] [c] | Takahashi, N. 2021 [39] [b] | Ionescu, D.F. 2021 [40] [a] | ||||
| Day 25.–28. | MD from baseline | - | −19.0 ** | −18.8 ** | −21.4 * | −10.0 | −14.5 [b1] | −15.1 [b2] | - |
| LS mean difference from AD + placebo | −4.5 | −4.1 ** [b1] | −3.2 ** [b2] | −4.0 * | −3.6 | 0.6 [b1] | −0.9 [b2] | −3.7* | |
Abbreviations: AD—(standard-of-care) antidepressant; LS—least square; MD—mean difference. [a]—results for 84 mg. [b]—results for 56 [b1] and 84 [b2] mg, respectively. [c]—flexible doses, ranging from 56 to 84 mg. * statistically significant. ** statistical significance was not assessed as the primary endpoint was not met.